Title: PHARMACOKINETICS AND CLINICAL OUTCOMES OF TOBRAMYCIN IN ADULT
CYSTIC FIBROSIS PATIENTS WITH ACUTE PULMONARY EXACERBATION
Running title: ASSESSING TOBRAMYCIN IN CYSTIC FIBROSIS
Authors: Daniel J.G. Thirion, PharmD1,2, Kevin
Koloskoff, PharmD1,3, Jean-Alexandre Caissy,
BSc1,3, Elias Matouk, MD4, Amélie
Marsot, PhD1,3
Affiliations: 1Faculty of Pharmacy, Université de
Montréal, Montreal, Quebec, Canada; 2Pharmacy
Department, Royal Victoria Hospital, McGill University Health Centre,
Montreal, Quebec, Canada; 3Laboratoire STP2, Faculty
of Pharmacy, Université de Montréal, Montreal, Quebec, Canada;4Adult Cystic Fibrosis Clinic, Montreal Chest
Institute, McGill University, Montreal, Quebec, Canada
Corresponding author:
Amelie Marsot: Faculty of Pharmacy, Université de Montréal, PO Box 6128,
succ. Centre-ville, Montreal, Quebec, Canada H3C 3J7
E-mail:
amelie.marsot@umontreal.ca
Telephone: 1-514-343-6111 ext. 5207
Fax: 1-514-343-6120
The data of this manuscript was presented as an abstract at the North
American Cystic Fibrosis Conference, Oct 21-23, 2020, online.
This research did not receive any specific grant from funding agencies
in the public, commercial, or not-for-profit sectors.
The authors declare no conflicts of interest.
Key points:
The evaluation of regimens through their predictive attainment of PK/PD
targets remains the fastest way to evaluate a dosing strategy and its
factors.
Clinically history of APEs is predictive of clinical outcomes.
CF-specific variability is likely to cause the current tobramycin dosing
regimen to be sub-optimal, rigorous identification of additional factors
is needed to account for this variability.